Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 9/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27412409 | 0.88 | SIRT6 (0.59) | SIRT6MAPTALDH1A1POLBLMNA | |
| SCHEMBL6151230 | 0.82 | SIRT6 (0.81) | SIRT6MAPTALDH1A1POLBLMNA | |
| SCHEMBL15271381 | 0.82 | SIRT6 (0.81) | SIRT6MAPTALDH1A1POLBLMNA | |
| SCHEMBL374222 | 0.80 | SIRT6 (0.68) | SIRT6MAPTALDH1A1POLBLMNA | |
| SCHEMBL4822106 | 0.77 | SIRT6 (0.60) | SIRT6MAPTALDH1A1POLBLMNA | |
| SCHEMBL4822111 | 0.77 | MAPT (0.56) | SIRT6MAPTALDH1A1POLBLMNA | |
| SCHEMBL447471 | 0.77 | SIRT6 (1.00) | SIRT6MAPTALDH1A1POLBLMNA | |
| SCHEMBL12240580 | 0.77 | SIRT6 (0.74) | SIRT6MAPTALDH1A1POLBLMNA | |
| SCHEMBL1045292 | 0.77 | SIRT6 (0.69) | SIRT6MAPTALDH1A1POLBLMNA | |
| SCHEMBL4248705 | 0.77 | MAPT (0.69) | SIRT6MAPTALDH1A1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1757590-B1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INST SCI & TECH (KR) | 2009-12-02 | — | — | EP | disclosed |
| US-7544686-B2 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-06-09 | — | — | US | disclosed |
| US-20070049604-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-03-01 | — | — | US | disclosed |
| EP-1757590-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | Korea Institute of Science and Technology (KR) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049604-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | CACNA1I, CACNA1G, CACNA1H | SIRT6 3624/4885MAPT 2721/4885ALDH1A1 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.